Lama2 Muscular Dystrophy Cn381166
A form of congenital muscular dystrophy causing severe muscle weakness starting in infancy. Affects motor development and can involve the brain. Treatment includes physical therapy, respiratory support, and multidisciplinary care.
Key facts at a glance
- ICD-10
- Q79.9
- ICD-11
- LA00.0
- Body system
- musculoskeletal
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Joint pain or stiffness
(musculoskeletal)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
muscle weakness
(musculoskeletal)delayed motor milestones
(musculoskeletal)hypotonia
(musculoskeletal)calf muscle pseudohypertrophy
(musculoskeletal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Muscle-Strengthening and Stretching Program
Regular physical therapy including passive stretching, strengthening exercises, and mobility work helps maintain function, prevent contractures, and slow disease progression. Therapy should be consistent and adapted to disease stage.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Respiratory Function Monitoring
Regular pulmonary function testing and overnight oximetry detect respiratory muscle weakness early, allowing timely intervention. Respiratory complications are a major cause of morbidity in Lama2-related muscular dystrophy.
Additional treatment options
Non-Invasive Ventilation Support
BiPAP or other non-invasive ventilation is initiated when respiratory function declines, particularly during sleep. This support reduces work of breathing and prevents nocturnal hypoventilation and its complications.
procedureNutritional Management
Dietary assessment and management address swallowing difficulties, constipation, and weight maintenance. Proper nutrition supports overall health and can help manage feeding difficulties common in this condition.
dietaryCorticosteroid Therapy
Glucocorticoids such as deflazacort or prednisone may be used to slow disease progression and maintain muscle function. Benefits include delayed loss of ambulation and prolonged respiratory function.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Lama2 Muscular Dystrophy Cn381166?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Lama2 Muscular Dystrophy Cn381166. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy